Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, Clorox Co’s stock clocked out at $118.97, up 1.10% from its previous closing price of $117.67. In other words, the price has increased by $1.10 from its previous closing price. On the day, 1.79 million shares were traded. CLX stock price reached its highest trading level at $119.1326 during the session, while it also had its lowest trading level at $117.905.
Ratios:
To gain a deeper understanding of CLX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 87.13 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 19.12. For the most recent quarter (mrq), Quick Ratio is recorded 0.57 and its Current Ratio is at 0.84. In the meantime, Its Debt-to-Equity ratio is 9.04 whereas as Long-Term Debt/Eq ratio is at 8.75.
Jefferies Upgraded its Hold to Buy on October 01, 2024, whereas the target price for the stock was revised from $174 to $187.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 07 ’25 when Breber Pierre R bought 4,000 shares for $136.57 per share. The transaction valued at 546,285 led to the insider holds 4,000 shares of the business.
Marriner Kirsten sold 7,494 shares of CLX for $1,136,251 on Mar 10 ’25. The EVP – Chief People Officer now owns 27,038 shares after completing the transaction at $151.62 per share. On Mar 11 ’25, another insider, Marriner Kirsten, who serves as the EVP – Chief People Officer of the company, sold 733 shares for $150.00 each. As a result, the insider received 109,950 and left with 26,305 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLX now has a Market Capitalization of 14551101440 and an Enterprise Value of 17461151744. As of this moment, Clorox’s Price-to-Earnings (P/E) ratio for their current fiscal year is 18.23, and their Forward P/E ratio for the next fiscal year is 17.08. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.05 while its Price-to-Book (P/B) ratio in mrq is 45.47. Its current Enterprise Value per Revenue stands at 2.458 whereas that against EBITDA is 12.499.
Stock Price History:
The Beta on a monthly basis for CLX is 0.52, which has changed by -0.24348211 over the last 52 weeks, in comparison to a change of 0.1590569 over the same period for the S&P500. Over the past 52 weeks, CLX has reached a high of $171.37, while it has fallen to a 52-week low of $117.35. The 50-Day Moving Average of the stock is -4.04%, while the 200-Day Moving Average is calculated to be -17.03%.
Shares Statistics:
It appears that CLX traded 1.82M shares on average per day over the past three months and 1651380 shares per day over the past ten days. A total of 122.69M shares are outstanding, with a floating share count of 121.91M. Insiders hold about 0.32% of the company’s shares, while institutions hold 90.41% stake in the company. Shares short for CLX as of 1755216000 were 6785896 with a Short Ratio of 3.72, compared to 1752537600 on 5759586. Therefore, it implies a Short% of Shares Outstanding of 6785896 and a Short% of Float of 6.34.
Dividends & Splits
With its trailing 12-month dividend rate of 4.9, CLX has a forward annual dividend rate of 4.90. Against a Trailing Annual Dividend Yield of 0.04164188The stock’s 5-year Average Dividend Yield is 3.01. The current Payout Ratio is 75.19% for CLX, which recently paid a dividend on 2025-08-13 with an ex-dividend date of 2025-08-13. Stock splits for the company last occurred on 1999-08-24 when the company split stock in a 2:1 ratio.
Earnings Estimates
The company has 14.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $1.54, with high estimates of $1.77 and low estimates of $1.4.
Analysts are recommending an EPS of between $6.3 and $5.88 for the fiscal current year, implying an average EPS of $6.11. EPS for the following year is $6.95, with 16.0 analysts recommending between $7.76 and $6.38.
Revenue Estimates
In the current quarter, 12 analysts expect revenue to total $1.42B. It ranges from a high estimate of $1.45B to a low estimate of $1.39B. As of the current estimate, Clorox Co’s year-ago sales were $1.76BFor the next quarter, 12 analysts are estimating revenue of $1.65B. There is a high estimate of $1.7B for the next quarter, whereas the lowest estimate is $1.62B.
A total of 17 analysts have provided revenue estimates for CLX’s current fiscal year. The highest revenue estimate was $6.59B, while the lowest revenue estimate was $6.43B, resulting in an average revenue estimate of $6.52B. In the same quarter a year ago, actual revenue was $7.1BBased on 16 analysts’ estimates, the company’s revenue will be $6.81B in the next fiscal year. The high estimate is $6.98B and the low estimate is $6.63B.
